Treatment of Hepatopancreatobiliary Cancers: Open Question, Challenge, and Future Directions (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 134
Special Issue Editors
Interests: carcinoma; hepatocellular; liver neoplasms; transplant oncology; neoadjuvant and adjuvant therapy; artificial intelligence; cholangiocarcinoma; colorectal and non-colorectal liver metastasis; pancreatic neoplasms
Special Issues, Collections and Topics in MDPI journals
Interests: carcinoma; hepatocellular; liver neoplasms; transplant oncology; neoadjuvant and adjuvant therapy; artificial intelligence; cholangiocarcinoma; colorectal and non-colorectal liver metastasis; pancreatic neoplasms
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of a previous Special Issue entitled “Treatment of Hepatopancreatobiliary Cancers: Open Question, Challenge, and Future Directions”.
Rates of hepatopancreaticobiliary (HPB) malignancies are increasing. Surgery is the cornerstone of treatment. However, only marginal improvements in patient survival have been achieved over the past few decades. The anatomical localisation of tumours in the vicinity of critical vascular structures, disease diffusion (e.g., peritoneal carcinomatosis, oligometastatic disease), and aggressive tumour biology are often responsible for poor outcomes. Recently, more aggressive approaches have been adopted, including extensive vascular resection, neoadjuvant treatments, and locoregional therapies. Liver transplantation (LT) is a well-recognised hepatocellular carcinoma (HCC) treatment and is increasingly being used in cholangiocarcinoma and colorectal liver metastases. Minimally invasive and ablative therapies are adjuncts or even replacements for resection. More recently, artificial intelligence in HPB surgery has shown promising implications in diagnosis and targeted treatment.
This Special Issue will focus on these extended indications and novel therapeutic approaches, as they are vital for improving the prognosis of these detrimental malignancies.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Role of surgery in localised and borderline resectable tumours;
- Management of colorectal and non-colorectal hepatic metastases;
- Treatment of oligometastatic disease (peritoneal carcinomatosis from hepatobiliary cancer);
- Complex surgery and extended resection;
- Centralisation and tumour board role;
- Neoadjuvant vs. adjuvant treatment (chemotherapy, locoregional therapy, target therapy, RFA);
- Adjuvant treatment;
- Transplant oncology;
- Artificial intelligence in HPB surgery.
We look forward to receiving your contributions.
Dr. Francesco Giovinazzo
Dr. Stijn van Laarhoven
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- carcinoma
- hepatocellular
- liver neoplasms
- transplant oncology
- neoadjuvant and adjuvant therapy
- artificial intelligence
- cholangiocarcinoma
- colorectal and non-colorectal liver metastasis
- pancreatic neoplasms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
